Status
Conditions
Treatments
About
The purpose of this pre-market clinical study is to evaluate the performance (efficacy) and safety of an autonomous blood drawing device (Venipuncture Device).
The study consists of several phases (A, B1, B2, C1, C2, 0).
Phase B1 is a confirmatory, Pivotal Clinical Study, required for regulatory approval, in which non-inferiority should be demonstrated in comparison to manual blood drawing.
Phases A, B2, C1, C2 are all exploratory studies, in which the technology and usability is further improved and tested. Phase 0 is an exploratory study for non-invasive technology testing (for example for improvement of ultrasound detection).
The study locations are outpatient blood drawing departments, in which patients are included as subjects. Additionally, in Phase A and C1, a small number of volunteers is included in a non-hospital site (Vitestro Site).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• Age ≥16 years.
Exclusion criteria
The following contra-indications / exclusion criteria are respected per arm:
In case the test subject has a suitable contralateral arm, the subject can be included in this study. In Study Phase B2, a manual venipuncture and automated venipuncture are performed in both arms. Patients who have a contra-indication in one arm are excluded from the Phase B2 study.
Primary purpose
Allocation
Interventional model
Masking
13,618 participants in 1 patient group
Loading...
Central trial contact
Luuk Giesen, MD; Jeroen Roest, MSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal